Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into the challenges of treating older patients with Hodgkin lymphoma (HL), including the increased risk of lung toxicity associated with bleomycin in these patients, and the challenge of treating those who are not fit for anthracycline-based regimens. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Received honoraria for speaker and advisory work from: Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio Received research funding from: BMS, MSD, Pfizer, Amgen, Celgene, Beigene